Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
Top Cited Papers
Open Access
- 23 April 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 382 (17), 1653-1659
- https://doi.org/10.1056/nejmsr2005760
Abstract
The renin–angiotensin–aldosterone system (RAAS) is an elegant cascade of vasoactive peptides that orchestrate key processes in human physiology. Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and SARS-CoV-2, which have been responsible for the SARS epidemic in 2002 to 2004 and for the more recent coronavirus disease 2019 (Covid-19) pandemic, respectively, interface with the RAAS through angiotensin-converting enzyme 2 (ACE2), an enzyme that physiologically counters RAAS activation but also functions as a receptor for both SARS viruses.1,2 The interaction between the SARS viruses and ACE2 has been proposed as a potential factor in their infectivity,3,4 and there are concerns about the use of RAAS inhibitors that may alter ACE2 and whether variation in ACE2 expression may be in part responsible for disease virulence in the ongoing Covid-19 pandemic.5-8 Indeed, some media sources and health systems have recently called for the discontinuation of ACE inhibitors and angiotensin-receptor blockers (ARBs), both prophylactically and in the context of suspected Covid-19.This publication has 70 references indexed in Scilit:
- Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63Journal of General Virology, 2012
- Soluble Angiotensin-Converting Enzyme 2 in Human Heart Failure: Relation With Myocardial Function and Clinical OutcomesJournal of Cardiac Failure, 2009
- SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARSEuropean Journal of Clinical Investigation, 2009
- Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartanAmerican Journal of Physiology-Renal Physiology, 2009
- Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted RatHypertension, 2006
- Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Myocardial infarction increases ACE2 expression in rat and humansEuropean Heart Journal, 2005
- Importance of Rapid and Effective Reduction of Blood Pressure in Treating Hypertension for the Prevention of Cardiovascular DiseasesHigh Blood Pressure & Cardiovascular Prevention, 2005
- The VALUE trial: a commentaryJournal of the Renin-Angiotensin-Aldosterone System, 2004
- Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II ReceptorsHypertension, 2004